荣昌生物制药（烟台）股份有限公司

Home
About Us
RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang a Canadian-American scientist. RemeGen is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States.

■Our Company ■Our Vision ■Board of Directors ■Management Team
Products/R&D Pipelines
Telitacicept

The World’s First Innovative Dual-Target Biological Medication to Treat Systemic Lupus Erythematosus

Disitamab Vedotin

The First Independently Developed Novel ADC Drug in China

■Marketed Products ■Marketing Team ■Product Pipeline
Science&Manufacturing
■Innovation Capacity ■Technology Platform ■Manufacturing ■Quality System ■Talent Team
Investors

STAR Market stock code：荣昌生物：688331.SH

【2024.05.07】 Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

HKEX stock code 荣昌生物：09995.HK

【2024.04.26】 [Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

■Financial Reports ■Circulars ■Activities and Presentations

■Investor Events Calendar ■Corporate Governance ■Investor Relation Contact Information
News
- Company News
- Media Reports
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv

■Company News ■Media Reports
Join Us
■Recruitment ■Working at RemeGen ■Compensation and Benefits
Contact Us
■Yantai, China

Address: No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.

Telephone:（+86）535-3573511

■Company Address ■Clinical Trial ■Human Resource ■ Adverse Reactions Reporting

News

< 1/6 >

Telitacicept

Disitamab Vedotin

ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China

RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

2025 ASCO ｜ Selected in Rapid Oral Abstract Presentation: Disitamab Vedotin as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer Achieves Efficacy Breakthrough

2025 ASCO | RemeGen Announces Trial Results of c-Met Targeted ADC for Treatment of Non-small Cell Lung Cancer

RemeGen’s Telitacicept Approved for Treatment of Myasthenia Gravis in China

RemeGen’s Novel ADC Drug RC278’s Clinical Trial Application Accepted

Poised to Reshape Treatment Landscape: A Phase 3 Clinical Trial on Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS